Venture Leaders Biotech 2024: 10 innovative startups selected for the Boston roadshow
The Swiss National Startup Team welcomes new members: 10 startups have been selected for the Venture Leaders Biotech 2024. The entrepreneurs will meet international investors and industry leaders during their roadshow and access industry-specific expertise to grow their ventures.
Selected from over 70 applications by a jury of investors and biotech experts, the ten startups will join the roadshow in Boston, one of the world's most important life science hubs. From May 13 to May 17, 2024, the roadshow will connect the participants with international investors and industry leaders, accelerating their ventures' expansion in the US.The Venture Leaders Biotech will introduce themselves and their startups at a kick-off event at the Swiss Biotech Day in Basel on April 22, 2024.
The startups will follow in the footsteps of high-flying former team members such as Covagen (acquired by Johnson & Johnson), Versantis (acquired by Genfit), SimplicityBio (acquired by Precision for Medicine), AMAL Therapeutics (acquired by Boehringer Ingelheim), NBE-Therapeutics (acquired by Boehringer Ingelheim), Alentis (USD 105 million funding round in 2023), and Interax Biotech (Seed round with US investors met during the roadshow). With the biotech industry comprising 39% of Swiss exports, the Venture Leaders Biotech program contributes to the enduring strength and vitality of the sector.
“Preparing for this roadshow for the 18th year is a tribute to the quality of innovation and startups that have been part of this journey,” shared Jordi Montserrat, Co-Founder and CEO of Venturelab. “I can’t wait to join this new edition and support this new team in their international expansion.”
"Thanks to our preparation during the roadshow, we engaged with VCs and pharma contacts, giving us invaluable exposure. Our team's mix of youth and experience taught us to thrive together," commented Mamta Chabria, Co-founder and CEO of Tandem Therapeutics and Venture Leaders Biotech 2023 participant.
Venture Leaders Biotech is organized by Venturelab in partnership with Swissnex in Boston and supported by Debiopharm, EPFL, ETH Zurich, Hansjörg Wyss, Kellerhals Carrard, Novartis, Swiss Biotech Association, and VISCHER.
Follow the entrepreneurs and the Venture Leaders Biotech roadshow on social media using the hashtag #VLeadersBiotech or on https://www.venturelab.swiss/venture-leaders-biotech.
About Venture Leaders
The Venture Leaders – Swiss National Startup Team members – have a clear goal: they want to take the first step towards international expansion, envisioning themselves as global players. Venturelab has 18 years of experience bringing Switzerland’s best entrepreneurs to the heart of technology hotspots: Silicon Valley, Boston, China, London, Barcelona, and Munich. Companies founded by the 500 Venture Leaders alumni have created more than 9,800 jobs and raised more than CHF 7.6 billion in capital. For more information, visit https://www.venturelab.swiss/ventureleaders. Discover all the alumni here.
Adoram Therapeutics SA: Multi-asset pre-clinical stage Biotech startup
Adoram Therapeutics is a spin-off from the University of Geneva, discovering next generation small molecule therapies for cancer and inflammation based around GPCR drug targets, the largest class of r... Read more
Allegria Therapeutics AG: Therapeutics that modulate mast cell activity
Allegria Therapeutics is a Basel-based biopharma startup established in 2023 with a commitment to build a differentiated portfolio of therapeutic approaches around biological targets that modulate mas... Read more
EVIIVE AG: Next-generation liquid biopsy solutions.
Our startup specializes in the cutting-edge field of extracellular vesicle (EV) biomarker discovery, utilizing single EV analysis and machine learning to revolutionize precision medicine. We provide a... Read more
inSEIT AG: Enzyme immobilization for green industrial production
inSEIT (integral Service for Enzyme Immobilization Technologies) offers services focused on the screening, application and scaling up of enzyme immobilization to ensure the practical implementation in... Read more
KYLYS AESTHETICS SA: Revolutionizing Skin Filling Science
KYLYS AESTHETICS offers a biocompatible hyaluronan-based and thermosensitive dermal filler that has the ability to form microgel structures in the tissue, resulting in a long-lasting effect and no mig... Read more
OBaris AG: Providing a painless alternative to injectable drugs.
Our unique platform aims at shifting the current paradigm from injectables to a simple, non-invasive formulation that enables safe and efficacious delivery of a variety of macromolecular drugs across ... Read more
Shape Biopharmaceuticals AG: A new class of immunotherapies based on nanoparticles.
At Shape, we're pioneering a breakthrough in healthcare with proprietary engineered SHAPEnano particles, leveraging the immune system of patients to produce therapeutic antibodies directly inside thei... Read more
TissueLabs SA: The platform for creating organs and tissues in the lab.
TissueLabs is dedicated to building the platform for creating organs and tissues in the lab. We provide biomaterials, equipment, and services to support tissue engineering and regenerative medicine. O... Read more
Virometix AG: Redefining Immunotherapy
A new platform technology called Synthetic Virus-Like Particle (SVLP) technology for synthetic vaccine design has been developed. The technology has the potential to revolutionize vaccine design. The ... Read more
Well Science AG: Natural immune support against allergic rhinitis
Founded in Freienbach, Switzerland in 2022, with support from the Nestlé R&D accelerator and the Swiss incubator firm Stryber, Well Science AG is on a mission to develop innovations to change the cour... Read more
Ymmunobio AG: First in class oncology drugs for unmet need
Ymmunobio has identified a new tumor marker with superior properties: 1. It is present in at least 13 solid tumors 2. It has a prevalence of up to 98% in cancer patients 3. It is not expressed by n... Read more
Related articles
Venture Leaders Biotech 2024: Captains Blog by Maria Van Dongen, CEO of Allegria Therapeutics, and Gabriel Liguori, CEO of TissueLabs
read more
Venture Leaders Biotech scale new heights in Boston
read more
EVIIVE: The Venture Leader Biotech developing the next-generation liquid biopsy solution
read more
TissueLabs: The Venture Leader Biotech fabricating lab-grown tissues for research and therapeutic applications
read more
Allegria Therapeutics secures USD 3.5 million Seed Financing to drive innovation in mast cell-mediated disease treatment
read more
Ymmunobio: The Venture Leader Biotech developing on first-in-class cancer therapies
read more
KYLYS AESTHETICS: The Venture Leader Biotech revolutionizing skin filling science
read more
Allegria Therapeutics: The Venture Leader Biotech modulating mast cell activity
read more
Adoram Therapeutics: The Venture Leaders Biotech creating new treatments for patients with solid tumors or immune-based diseases
read more